Journal article
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Clinical infectious diseases, Vol.80(1), pp.223-227
02/05/2025
DOI: 10.1093/cid/ciae465
PMCID: PMC11797383
PMID: 39325506
Abstract
For COVAIL recipients of a COVID-19 Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
Details
- Title: Subtitle
- Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
- Creators
- Youyi Fong - Fred Hutch Cancer CenterLauren Dang - National Institute of Allergy and Infectious DiseasesBo Zhang - Fred Hutch Cancer CenterJonathan Fintzi - National Institute of Allergy and Infectious DiseasesShiyu Chen - Fred Hutch Cancer CenterJing Wang - Frederick National Laboratory for Cancer ResearchNadine G Rouphael - Emory UniversityAngela R Branche - University of RochesterDavid J Diemert - George Washington UniversityAnn R Falsey - University of RochesterCecilia Losada - HOPE ClinicLindsey R Baden - Brigham and Women's HospitalSharon E Frey - Saint Louis UniversityJennifer A Whitaker - Baylor College of MedicineSusan J Little - University of California San DiegoSatoshi Kamidani - Emory UniversityEmmanuel B Walter - Duke UniversityRichard M Novak - University of Illinois ChicagoRichard Rupp - The University of Texas Medical Branch at GalvestonLisa A Jackson - Kaiser Permanente Washington Health Research InstituteChenchen Yu - Fred Hutch Cancer CenterCraig A Magaret - Fred Hutch Cancer CenterCindy Molitor - Fred Hutch Cancer CenterBhavesh Borate - Fred Hutch Cancer CenterTara M Babu - University of WashingtonAngelica C Kottkamp - New York UniversityAnne F Luetkemeyer - University of California, San FranciscoLilly C Immergluck - Morehouse School of MedicineRachel M Presti - Washington University in St. LouisMartín Bäcker - Long Island UniversityPatricia L Winokur - University of IowaSiham M Mahgoub - Howard University HospitalPaul A Goepfert - University of Alabama at BirminghamDahlene N Fusco - Tulane UniversityRobert L Atmar - Baylor College of MedicineChristine M Posavad - Fred Hutch Cancer CenterJinjian Mu - Emmes (United States)Mat Makowski - Emmes (United States)Mamodikoe K Makhene - National Institute of Allergy and Infectious DiseasesSeema U Nayak - National Institute of Allergy and Infectious DiseasesPaul C Roberts - National Institute of Allergy and Infectious DiseasesDean Follmann - National Institute of Allergy and Infectious DiseasesPeter B Gilbert - Fred Hutch Cancer CenterCoronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team
- Resource Type
- Journal article
- Publication Details
- Clinical infectious diseases, Vol.80(1), pp.223-227
- DOI
- 10.1093/cid/ciae465
- PMID
- 39325506
- PMCID
- PMC11797383
- NLM abbreviation
- Clin Infect Dis
- ISSN
- 1058-4838
- eISSN
- 1537-6591
- Publisher
- OXFORD UNIV PRESS INC
- Grant note
- UM1 AI148685 / NIAID NIH HHS
- Language
- English
- Electronic publication date
- 09/26/2024
- Date published
- 02/05/2025
- Academic Unit
- Infectious Diseases; Medicine Administration; Internal Medicine
- Record Identifier
- 9984721241302771
Metrics
5 Record Views